Indoco Remedies Reports Q2 FY27 Profit of Rs 19.47 Crore

Consolidated revenue stood at Rs 506.92 crore, rising 7.4% from Rs 471.83 crore last year.
Net profit reached Rs 19.47 crore, a turnaround from the Rs 9.21 crore loss in Q2 FY26.

Reader Takeaway: Strong growth in international formulations and API segments offset by concerns over negative net worth of subsidiaries.

What just happened

Indoco Remedies has announced its financial results for the quarter ended September 30, 2026. The company reported a net profit of Rs 19.47 crore for Q2 FY27, marking a shift back to profitability. The results include a one-time exceptional gain of Rs 36.63 crore from the sale of a property in Andheri (East), Mumbai. Standalone revenue for the quarter was reported at Rs 438.06 crore with a standalone net profit of Rs 30.63 crore.

Why this matters

The return to profitability suggests a stabilizing operational performance, supported by specific high-growth segments. The sale of non-core property assets has provided a significant cash infusion, assisting the bottom line in the current quarter.

Growth Drivers

Management highlighted strong momentum in key business units:

• International formulations business recorded 21.1% growth in Q2.
• API segment saw a 22.0% revenue increase during H1 FY27.
• Allied services segment grew by 27.4% in H1 FY27.

Risks to watch

Statutory auditors have raised an 'Emphasis of Matter' regarding the negative net worth of two subsidiaries: FPP Holding LLC and Warren Remedies Private Limited. Although management stated that impairment testing showed no immediate need for provisions, the long-term financial health of these entities remains a point of concern for investors.

What to track next

Investors should monitor whether the growth trends in international formulations and the API segment can sustain momentum in the absence of one-time gains. Further updates on the operational turnaround of the loss-making subsidiaries will be critical for long-term valuation.